
1. int j tuberc lung dis. 2001 dec;5(12):1109-15.

design regimens treating tuberculosis patients hiv infection, with
particular reference sub-saharan africa.

harries ad(1), hargreaves nj, salaniponi fm.

author information: 
(1)national tuberculosis control programme, ministry health, lilongwe, malawi.
adharries@malawi.net

the highest burden human immunodeficiency virus (hiv) related tuberculosis
(tb) sub-saharan africa. hiv complicates several areas tb control, one
of involves treatment treatment outcome. large patient numbers cause
congestion tb wards, increased morbidity, increased risk of
adverse drug reactions, increased case fatality, increased recurrence
of tb treatment completion. tb control programmes responded these
problems taking actions abolishing thioacetazone decentralising
the initial phase treatment peripheral health centres community.
despite response, three major on-going concerns need be
addressed research studies. need reduce case fatality rates
focusing 1) stronger treatment regimens, 2) adequacy rifampicin levels when
intermittent treatment regimens used, 3) adjunctive treatments. 
a need reduce recurrent rates tb 1) determining relative role of
re-infection reactivation cause recurrence, 2) assessing the
importance duration type anti-tb treatment first episode tb,
and 3) determining role secondary isoniazid preventive therapy. a
need evaluate best decentralise treatment perspective the
health service patient. research studies relevant needs 
and resources tb control programmes, include pharmacokinetic
studies, controlled clinical trials operational research, including economic 
analysis social science evaluation.


pmid: 11769768  [indexed medline]

